USITC to investigate blood separation devices
The US International Trade Commission (ITC) has instituted an investigation into certain blood separation and cell preparation devices.
In a notice of investigation yesterday, March 7, the ITC said the investigation was based on a complaint filed by biotechnology company RegenLab on February 4.
RegenLab named two medical technology companies—Israel-based Estar Technologies and Texas-based Eclipse MedCorp—in its complaint.
It said the companies had imported and sold devices in the US that infringed one of its patents (US number 10,064,894) which covers methods and devices for cell preparations.
According to RegenLab, the companies’ sold “blood separation and cell preparation devices that allow clinicians to collect a patient’s blood and separate platelet rich plasma from the blood”.
The ITC said Estar and Eclipse must submit responses to the complaint within 20 days.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk